Brown PO, Palmer C: The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009, 6: e1000114-10.1371/journal.pmed.1000114.
Article
PubMed
PubMed Central
Google Scholar
Davis HM, Zurawski VR, Bast RC, Klug TL: Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res. 1986, 46: 6143-6148.
CAS
PubMed
Google Scholar
Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, et al: New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005, 15: 274-281. 10.1111/j.1525-1438.2005.00441.x.
Article
PubMed
Google Scholar
Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC: Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984, 148: 1057-1058.
Article
CAS
PubMed
Google Scholar
Park Y, Lee JH, Hong DJ, Lee EY, Kim HS: Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011, 44: 884-888. 10.1016/j.clinbiochem.2011.04.011.
Article
CAS
PubMed
Google Scholar
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, et al: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010, 28: 2159-2166. 10.1200/JCO.2008.19.2484.
Article
PubMed
PubMed Central
Google Scholar
Cree I: Improved blood tests for cancer screening: general or specific?. BMC Cancer. 2011, 11: 499-10.1186/1471-2407-11-499.
Article
PubMed
PubMed Central
Google Scholar
Kulasingam V, Pavlou MP, Diamandis EP: Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer. 2010, 10: 371-378. 10.1038/nrc2831.
Article
CAS
PubMed
Google Scholar
Lu R, Sun M, Feng J, Gao X, Guo L: Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer. 2011, 11: 270-10.1186/1471-2407-11-270.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer. 2010, 10: 64-10.1186/1471-2407-10-64.
Article
PubMed
PubMed Central
Google Scholar
Helistrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63: 3695-3700.
Google Scholar
Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65: 2162-2169. 10.1158/0008-5472.CAN-04-3924.
Article
CAS
PubMed
Google Scholar
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008, 108: 402-408. 10.1016/j.ygyno.2007.10.017.
Article
CAS
PubMed
Google Scholar
Holcomb K, Vucetic Z, Miller MC, Knapp RC: Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011, 205 (358): e351-e356.
Google Scholar
Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, et al: Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011, 20: 2496-2506. 10.1158/1055-9965.EPI-11-0635.
Article
CAS
PubMed
PubMed Central
Google Scholar
Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I: HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011, 104: 863-870. 10.1038/sj.bjc.6606092.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009, 112: 40-46. 10.1016/j.ygyno.2008.08.031.
Article
CAS
PubMed
Google Scholar
Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC: The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med. 2011, 49: 521-525.
Article
CAS
PubMed
Google Scholar
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283: 2008-2012. 10.1001/jama.283.15.2008.
Article
CAS
PubMed
Google Scholar
Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JHP, Bossuyt PMM: Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999, 282: 1061-1066. 10.1001/jama.282.11.1061.
Article
CAS
PubMed
Google Scholar
Benedet JL, Pecorelli S: Why cancer staging? FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006, 95 (Suppl 1): S3-
Article
PubMed
Google Scholar
Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MMG, Sterne JAC, Bossuyt PMM: Group tQ-: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011, 155: 529-536.
Article
PubMed
Google Scholar
Whiting P, Harbord R, Kleijnen J: No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol. 2005, 5: 19-10.1186/1471-2288-5-19.
Article
PubMed
PubMed Central
Google Scholar
Chappell FM, Raab GM, Wardlaw JM: When are summary ROC curves appropriate for diagnostic meta-analyses?. Stat Med. 2009, 28: 2653-2668. 10.1002/sim.3631.
Article
CAS
PubMed
Google Scholar
Rutter CM, Gatsonis CA: A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001, 20: 2865-2884. 10.1002/sim.942.
Article
CAS
PubMed
Google Scholar
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH: Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005, 58: 982-990. 10.1016/j.jclinepi.2005.02.022.
Article
PubMed
Google Scholar
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327: 557-560. 10.1136/bmj.327.7414.557.
Article
PubMed
PubMed Central
Google Scholar
Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A: Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006, 6: 31-10.1186/1471-2288-6-31.
Article
PubMed
PubMed Central
Google Scholar
Leeflang MMG, Deeks JJ, Gatsonis C, Bossuyt PMM: Group obotCDTAW: Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008, 149: 889-897.
Article
PubMed
PubMed Central
Google Scholar
Deeks JJ, Macaskill P, Irwig L: The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005, 58: 882-893. 10.1016/j.jclinepi.2005.01.016.
Article
PubMed
Google Scholar
Dwamena BA: midas: Computational and Graphical Routines for Meta-analytical Integration of Diagnostic Accuracy Studies in Stata. 2007, Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor
Google Scholar
Roger M, Harbord PW: metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J. 2009, 9: 19-
Google Scholar
Abdel-Azeez HA, Labib HA, Sharaf SM, Refaie AN: HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2010, 11: 111-116.
PubMed
Google Scholar
Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, Ha M, Choi KH: Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case–control study in a Korean population. Clin Chem Lab Med. 2011, 49: 527-534.
CAS
PubMed
Google Scholar
Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, et al: Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 2011, 21: 852-858. 10.1097/IGC.0b013e31821a3726.
Article
PubMed
Google Scholar
Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, Heinzelmann-Schwarz V: No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011, 121: 487-491. 10.1016/j.ygyno.2011.02.022.
Article
CAS
PubMed
Google Scholar
Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, Skates SJ: Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011, 118: 280-288. 10.1097/AOG.0b013e318224fce2.
Article
PubMed
PubMed Central
Google Scholar
Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA: A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics. 2007, 8: 239-251.
Article
PubMed
Google Scholar
Dinnes J, Deeks J, Kirby J, Roderick P: A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess. 2005, 9 (iii): 1-113.
CAS
Google Scholar
Bolstad N, Oijordsbakken M, Nustad K, Bjerner J: Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012, 33: 141-148. 10.1007/s13277-011-0256-4.
Article
PubMed
Google Scholar
Galgano MT, Hampton GM, Frierson HF: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006, 19: 847-853.
CAS
PubMed
Google Scholar
Zhou Y, Yin X, Ying J, Zhang B: Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta- analysis. BMC Cancer. 2012, 12: 17-10.1186/1471-2407-12-17.
Article
CAS
PubMed
PubMed Central
Google Scholar